Clinical Trials Logo

Filter by:
NCT ID: NCT03995056 Completed - Exercise Clinical Trials

Exercise Study in Subjects With NAFLD

BestTreat
Start date: April 19, 2019
Phase: N/A
Study type: Interventional

Non-Alcoholic Fatty Liver Disease is the most common cause of chronic liver diseases. The benign non-alcoholic fatty liver, characterized by excessive fat accumulation, can evolve into non-alcoholic steatohepatitis and liver cancer. The recommendation nowadays is a lifestyle change with physical exercise and diet to reduce liver fat and improve inflammation. Besides this, a leaky gut and dysbiosis have an impact on the liver, and exercise ameliorates the diversity of gut microbiota and permeability of the intestine. The aim of this study is to find out a link between exercise and the gut-liver axis regarding the stage of liver adiposity and define exercise-responsive gut microbiome in NAFLD patients

NCT ID: NCT03993080 Completed - Dental Anxiety Clinical Trials

Virtual Reality Relaxation to Decrease Dental Anxiety

Start date: October 15, 2018
Phase: N/A
Study type: Interventional

The aim is to apply short-term virtual reality relaxation to examine if it is effective in reducing pre-operative dental anxiety in primary health care using an RCT.

NCT ID: NCT03980600 Completed - Clinical trials for Skin Transplantation

NFC Dressing for Skin Graft Donor Sites

FibDexHBC
Start date: February 16, 2015
Phase: N/A
Study type: Interventional

The aim of this single center clinical investigation was to optimize nanofibrillar cellulose (NFC) wound dressing and to investigate final product FibDex in the treatment of split thickness skin graft donor sites. Performance of NFC dressings Type 1, Type 2, Type 3 and Type 4 (final product, FibDex) was compared with that of Suprathel®.

NCT ID: NCT03979443 Completed - Clinical trials for Cervical Radiculopathy

Finnish Trial on Practices of Anterior Cervical Decompression (FACADE) Comparing Outpatient vs. Inpatient Care

FACADE
Start date: June 12, 2019
Phase: N/A
Study type: Interventional

FACADE is a prospective, randomized, controlled, parallel group non-inferiority trial comparing the traditional hospital surveillance (inpatient, patients staying in the hospital for 1-3 nights after surgery) to outpatient care (discharge on the day of the surgery, usually within 6-8 hours after procedure) in patients who have undergone anterior cervical decompression and fusion (ACDF) procedure.

NCT ID: NCT03979313 Completed - Clinical trials for Respiratory Syncytial Virus Infections

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

MELODY
Start date: July 23, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy late preterm and term infants who are 35 weeks or greater gestational age and entering their first RSV season.

NCT ID: NCT03971071 Completed - Migraine Headache Clinical Trials

A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

Start date: October 7, 2019
Phase: Phase 4
Study type: Interventional

Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are diagnosed with medication overuse headache (MOH).

NCT ID: NCT03968159 Completed - Clinical trials for Adjunctive Treatment of Major Depressive Disorder

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Start date: April 25, 2019
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have an inadequate response to antidepressant therapy

NCT ID: NCT03963687 Completed - Nursing Clinical Trials

Effectiveness of Web-based Genomic Nursing Education Intervention

Start date: January 20, 2020
Phase: N/A
Study type: Interventional

There is a research gap of integrating genomics into nursing practice, education and research. Nursing students seldom use genetic-genomic data for understanding the individuality of patients and utilize this in delivering personalized or individualized nursing care. Preparing future nurses in genetic-genomic competencies is a fundamental step for clinical application. This research project may help shape the future of the nursing profession in career development by preparing future nurses to emerging advance technologies in genetics-genomics.

NCT ID: NCT03961204 Completed - Clinical trials for Multiple Sclerosis (MS)

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

Start date: August 15, 2019
Phase: Phase 4
Study type: Interventional

The objective of this study was to collect data both retrospectively and prospectively in order to evaluate the long-term outcomes, durability of effect, and real-world treatment patterns following treatment with Cladribine Tablets or placebo in participants with multiple sclerosis (MS) who were previously participated in the parent studies (ORACLE MS and CLARITY/CLARITY-EXT).

NCT ID: NCT03959488 Completed - Clinical trials for Respiratory Syncytial Virus Infections

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Start date: July 30, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of MEDI8897 compared to palivizumab when administered to preterm infants entering their first RSV season and children with chronic lung disease (CLD) and congenital heart disease (CHD) entering their first and second RSV season.